Nektar(US:NKTR) ZACKS·2026-03-05 16:01Core Viewpoint - Nektar Therapeutics (NKTR) is anticipated to report a year-over-year decline in earnings due to lower revenues, which could significantly influence its near-term stock price depending on how actual results compare to consensus estimates [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for March 12, with expectations of a quarterly loss of $2.76 per share, reflecting a year-over-year change of -22.7% [3]. - Revenues are projected to be $9.54 million, down 67.3% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 7.57% higher in the last 30 days, indicating a reassessment by analysts [4]. - However, the Most Accurate Estimate for Nektar is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -48.28%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, but its predictive power is significant primarily for positive readings [9][10]. - Nektar's current Zacks Rank is 2 (Buy), but the negative Earnings ESP complicates predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Nektar was expected to post a loss of $2.85 per share but actually reported a loss of -$1.85, resulting in a positive surprise of +35.09% [13]. - Over the past four quarters, Nektar has beaten consensus EPS estimates twice [14]. Industry Context - In the Zacks Medical - Drugs industry, electroCore, Inc. (ECOR) is expected to report a loss of $0.35 per share for the same quarter, indicating a year-over-year change of +12.5% [18]. - electroCore's revenue is projected to be $9.26 million, up 31.4% from the previous year, but it has an Earnings ESP of -13.04% and a Zacks Rank of 4 (Sell), making predictions of an earnings beat difficult [19].